direct and indirect healthcare costs of type 2 diabetes in Austria. Methods: A burden of disease study, which evaluates all kinds of disease burden, like costs, quality adjusted life years (QALYs) and disability adjusted life years (DALYs) lost, was conducted. This study uses a prevalence-based bottom-up approach and projects costs over the time horizon of one year. Data were collected via literature review, published list prices and hospital records. Costs from published sources were used from the societal perspective. The direct costs include hospital, treatment and physician consultation costs. Indirect costs cover patient care giver costs as well as work absenteeism. Results: The average costs per year of a Diabetes Type 2 are 3,242.91 EUR. Inpatient care is a major contributor to costs, accounting for 81% of total costs while drug costs account for an average of 14%. The estimated total direct annual cost for all patients diagnosed with type 2 diabetes is 1.2 billion EUR. This represents a share of 3.3% of the country´s total healthcare expenditures. The average annual indirect costs for patients with diabetes mellitus type 2 amounts to 781 million EUR. Compared to the healthy population, the diabetes mellitus type 2 population have utility decrements of 251,974 QALYs. Moreover type 2 diabetes patients will lose 19,853 DALYs within one year. ConClusions: Type 2 diabetes mellitus is a common disease and the prevalence is expected to increase considerably in the future. The findings of this study demonstrate the high economic import of the disease.
objeCtives: Although type 2 diabetes (T2DM) has been globally recognised as a major public health issue with substantial economic implications, its quantitative impact in some geographical regions is not well documented. This study aimed to describe the health care resource utilisation (HCRU) associated with T2DM in Africa, Middle East, South Asia, Eurasia and Turkey. Methods: Crosssectional data from 8,156 patients recruited across four geographical regions (18 countries) was collected as part of the 5th wave of the IDMPS (2011) (2012) . Mean (SD) annual levels of different types of HCRU were estimated and negative binomial regression was undertaken to identify drivers of HCRU by region and country. Results: Estimated HCRU showed that patients in South Asia (n= 1,195) , Eurasia (n= 1,843), Africa (n= 2,220) Middle East (n= 2,065) and Turkey (n= 842) experienced a mean (SD) of 0.4 (1.5), 1.7 (4.1), 0.6 (1.9), 0.3 (1.2) and 1.3 (2.7) hospitalisations annually. The mean (SD) annual number of diabetes-related inpatient days was 1.5 (6.8), 16.0 (30.0), 4.7 (22.7), 1.1 (6.1) and 10.8 (34.3) respectively. The mean (SD) annual number of sick days due to diabetes for the same regions were 4.6 (19.7), 17.5 (35.4), 11.6 (44.4), 1.4 (6.8) and 8.0 (34.4). Presence of macrovascular complications was a key driver of incidence of hospitalisations [Incidence Rate Ratio -IRR (CI 95%)] in South Asia [3.4 (1.4-8.5 )], Eurasia [1.4 (1.1-1.8)], 3)], Middle East [8.9 (4.6-15.7)] and Turkey [2.9 (1.8-4.6)]. Microvascular complications were associated with increased risk of hospitalisations in all regions with IRRs (CI 95%) of 3.5 (1.8 -7.0), 3.4 (2.2 -5.1), 3.7 (2.2 -5.1), 1.7 (1.0 -2.9) and 3.4 (2.2 -5.1) respectively. ConClusions: Results of this study demonstrate that in South Asia, Eurasia, Africa, Middle East and Turkey, development of micro and macrovascular complications are key drivers for economic burden of T2DM.
PDB126
healthcare use anD exPenDIture for DIaBetes In BanglaDesh: a MatcheD-case-control stuDy Munich, Germany, Munich, Germany objeCtives: Diabetes imposes huge social and economic impact on nations. However, information on the costs of treating and managing diabetes in developing countries is limited. The aim of this study was to estimate healthcare use and expenditure for diabetes in Bangladesh. Methods: We conducted a matched case-control study between January and July 2014 among 591 adults with diagnosed diabetes mellitus (DMs) and 591 age, sex, and residence matched persons without diabetes mellitus (non-DMs). We recruited DMs from consecutive patients and non-DMs from accompanying persons in BIHS hospital in Dhaka, Bangladesh. We estimated the impact of diabetes on healthcare use and expenditure by calculating ratios and differences between DMs and non-DMs and tested for statistical difference using t-tests. Results: DMs had two times more days of inpatient treatment, 1.3 times more outpatient visits, and 9.7 times more medications than non-DMs (all p< 0.005). The total annual per capita expenditure on medical care was 6.12 times higher for DMs than non-DMs (USD 635 vs. 104, respectively). Among DMs, 9.8% reported not taking any antidiabetic medications, 46.4% took metformin, 38.7% sulphonylurea, 40.8% insulin, 38.7% any antihypertensive medication, and 14.2% took anti-lipids over the preceding 3 months. ConClusions: Diabetes significantly increases healthcare use and expenditure and is likely to impose a huge economic burden on the healthcare systems in Bangladesh. The study highlights the importance of prevention and optimum management of diabetes in Bangladesh, and other developing countries, to gain a strong economic incentive through implementing multi-sectoral approach and cost-effective prevention strategies.
PDB127 ePIDeMIology anD costs of PerIPheral arterIoPathy In DIaBetIc
PatIents: a PoPulatIon-BaseD stuDy literature, there is little if any attempt to quantify it. We aim to quantify the difference between the efficacy and effectiveness of Metformin in terms of reducing HbA1c in patients with type-2-diabetes. Methods: First, a systematic review was carried out to identify relevant randomized controlled trials (RCTs) and noninterventional studies (NIS). CENTRAL, MEDLINE (via PubMed) and clinicaltrials. gov were searched for relevant articles published within the last 20 years. RCTs and NIS which evaluated the treatment effects of Metformin in adult patients with type-2-diabetes and analyzed glycaemic control by means of change in HbA1c value were included. Studies in which Metformin was used as a concomitant antidiabetic, studies with a study period of less than three months and studies analyzing subpopulations were excluded from further research. Only German and English papers were eligible. Second, mean values of HbA1c reduction were aggregated in a meta-analysis using a random-effects model. Study heterogeneity was assessed by the I2-parameter. To test for publication bias we used funnel plots. Results: In total 1151 articles were identified. 21 RCTS and 6 NIS were included in the quantitative analysis. Overall HbA1c was reduced by 1.012% (95%-CI: -1.186%; -0.839%). I2 was 99.911% (RCTs: 99.932; NIS: 97.769) indicating high heterogeneity. The comparison of the two settings resulted in a small difference of 0.130% in HbA1c decrease between RCTs (-0.953%; 95%CI: -1.188%, -0.717%) and NIS (-1.083%; 95% CI: -1.34%, -0.826%). ConClusions: The results of our analysis indicate that the often-mentioned gap between clinical studies and real-world application does not exist in the treatment of type-2-diabetes with Metformin. Pharmacokinetic studies [MMW Spezial, Münch. med. Wschr. 1999, 141: page 2] showed that comparing with the standard formulation HRF of ALA reduces the inter-individual variability in absorption by 58% thus ensuring optimal absorption in most patients. The objective of the study was to assess the consumption of oral formulations of ALA preparations in the pharmaceutical market of Ukraine and to conduct pharmacoeconomic evaluation. Methods: The consumption of 2 oral formulations of ALA preparations was assessed in indicator DDDs/1000 inhabitants/day (DIDs). To conduct the pharmacoeconomic evaluation, results of pharmacokinetic studies were used [MMW Spezial, Münch. med. Wschr. 1999, 141: page 2] . Results: In 2013, the amount of consumption of ALA preparations in the pharmaceutical market of Ukraine was 1.79 DIDs. The portion of HR formulation accounts for 5.35% of the total amount of consumption and the consumption of the standard oral formulation of ALA preparations accounts for 94.65%, respectively. According to authors of the study, the indicator of the inter-individual variability in absorption was 22% for HRF and 59% -for standard ALA formulation. Thus NNT indicator is 1/0.37 = 2.7. Calculating the cost of achieving a therapeutically effective plasma level in 1 patient on the NNT indicates that the achievement of a therapeutic level in the blood plasma needs 2.7 times more costs when administering the standard ALA formulation compared to HRF. ConClusions: HR formulation of ALA has a higher cost effectiveness compared to the standard oral formulation, which makes it more efficient to use.
PDB123 IMProvIng the systeM of healthcare ProvIsIon for PatIents WIth hyPothyroIDIsM In ukraIne
Vadziuk I, Klishch I Ivan Horbachevsky Ternopil State Medical University, Ternopil, Ukraine objeCtives: To assess medical technologies in order to increase efficiency and reduce the cost of thyroid disease treatment. Methods: We made the retrospective analysis of 81 patients's medical records with hypothyroidism that were hospitalized to the endocrinology department of Ternopil University Hospital (Jan-Dec 2012). The cost of replacement therapy with levothyroxine drugs, which were preferred in practice, was analyzed. We also checked the appropriateness of diagnostics and specialist consultations according to the Protocol of medical care for patients with endocrine system disorders. Results: The result of retrospective analysis of 81 patients's medical records with hypothyroidism showed that all patients received replacement therapy by levothyroxine. Among them 74 patients were treated with drugs of Ukrainian production while 7 patients were taking medicine of foreign manufacturer. The cost of pharmacotherapy with foreign medicines was 125% more expensive compare to Ukrainian drugs. When comparing diagnostics and specialists consultations with a Protocol of medical care for patients with endocrine system disorders we have established compliance. However, given the prevalence of complications of underlying disease by cardiovascular system disorders (in 100% of patients), we consider it necessary to add cardiologist consultation to Protocol. ConClusions: It is advisable to use domestic drugs in pharmacotherapy of hypothyroidism. Cardiologist consultation should be added to Protocol of medical care for patients with hypothyroidism. objeCtives: To evaluate the prevalence and patterns of CAM use among diabetes patients in Pakistan. In addition, the study also focused on the perceived effectiveness of CAM over conventional therapies, information seeking behavior and CAM disclosure to healthcare providers. Methods: A prospective, crosssectional and self-administered questionnaire based study was conducted in tertiary care public hospitals in Pakistan. A prevalence based sample of 350 diabetes patients attending the tertiary hospital in Punjab, Pakistan were selected for the study. All obtained data were analyzed using descriptive and inferential statistics. Results: Overall, 327 questionnaires were completed and included in the analysis, showing that 52.8% of diabetics had used CAM, with most (62.4%) believing that CAM therapies assist body's natural forces to heal. CAM usage was significantly associated with gender (P= 0.001), level of education (P= 0.001), employment status (P= 0.03) and monthly income (P< 0.001). ConClusions: Diabetes treatment and management requires compliance to effective therapies at early stages. Healthcare providers should engage diabetics in an open non-judgmental dialogue to ascertain better understanding of diabetes and its management options.
PDB124

BurDen of DIsease of DIaBetes MellItus tyP-2 In austrIa
PDB131 hoW to DeterMIne the target PoPulatIon In early BenefIt assessMents In gerMany? the case of DIaBetes MellItus tyPe 2
Schwalm A 1 , Mostardt S 1 , Ten Thoren C 1 , Zhou M 1 , Gerber-Grote AU 2 1 IQWiG, Cologne, Germany, 2 Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany objeCtives: Since 2011, an early benefit assessment is required for all new drugs being launched in Germany. Evidence submitted by pharmaceutical companies in dossiers is assessed by the Institute for Quality and Efficiency in Health Care (IQWiG) and subsequently appraised by the German Federal Joint Committee (FJC). The exact determination of the patient target population plays an important role for subsequent price negotiations. In diabetes mellitus type 2 the size of target population varies considerably between dossiers. Our aim was to explore the reasons for these differences. Methods: We analyzed 20 dossiers with drugs for diabetes mellitus type 2 published between January 2012 and May 2015. Details regarding the estimation of the target population were extracted and compared. Based on the extractions a criteria list was developed to categorize possible reasons for different sizes of the target population. Results: The estimations of the target population were mainly based on secondary data analyses of drug prescriptions. The methods and assumptions used to analyze these data varied widely. Important reasons for differences in the estimations are the kind of database, the time frame, the operationalization of diabetes patients, the specification of the target population, the type of contraindications, the consideration of currently undetected patients, the mode of extrapolation to the overall population, and the portion of statutory health insurance patients. We could not identify one reason that could explain most of the deviations in the size of the target population. Several reasons seem to interact and it was not possible to determine the direction or size of the effect. ConClusions: There is a strong need for more detailed descriptions of the methods and databases used in the dossiers to estimate the size of the target populations. A harmonization of the methods seems to be helpful to reduce the variation.
PDB132 trIo h's (hyPerglyceMIa, hyPertensIon, hyPerlIPIDeMIa): unDIagnoseD MoDIfIaBle rIsk factors In MalaysIa rural coMMunIty
Lee YY, Lee L, Hong L, Welluppillai V, Kamarudin A Pfizer Malaysia, Kuala Lumpur, Malaysia objeCtives: Modifiable risk factors such as trio Hs are major contributor to the disease burden in Malaysia. Heart disease is number one leading cause of death in the country and individuals with diabetes are two to four times more likely to develop heart disease or stroke relative to those without diabetes. In view of severe multifold outcome caused by trio Hs, we aim to examine the prevalence of undiagnosed trio Hs and management of these risk factors among participants who had previously detected with these conditions. Methods: We retrospectively performed secondary data analysis on random selective samples from Pfizer Care-a-Van community health screening which was established in year 1999. Health screenings were conducted in mobile examination centers across the country by a team of registered physician, nurses, and volunteers along with various NGO partners. Standardized screening forms were used to collect demographic data and screening results. Participants with abnormal screening results will be referred to government clinics or hospitals for further tests and/or treatment. Descriptive analysis was performed using Stata 13. Results: A total of 7601 subjects were available for analysis from 2003 till 2014. Over half (58.4%) of the screening participants were female aged 45.8 years (SD, 14.4). 13.3% had been previously diagnosed with hyperlipidemia, while 10.6% and 13.1% were diabetic and hypertensive. Undiagnosed hyperlipidemia was reported at 56.5%, followed by hyperglycemia (32.5%) and hypertension (17.8%). Almost half (49.9%) of hypertensive and 59.2% hyperlipidemia subjects failed to achieve target blood pressure and cholesterol level whereas only 38.2% diabetic had their blood glucose under control. ConClusions: Multiple risk factors pose a significant burden objeCtives: The aim of this study was to assess the burden of peripheral arteriopathy (PA) in diabetic patients. Methods: Eligible patients were identified through a data warehouse (DENALI), which matches clinical and economic data of about 9.9 million individuals of Lombardy, a northern Italian region which represent 16.4% of the Italian population. The study population was made of all individuals over 40 with a diagnosis of diabetes who during the period 1-1-2002 to 31-12-2009 had an hospital admission (index event) attributable to PA disease. The identified individuals were followed-up from the index event to a maximum of 7 years. We evaluated demographic characteristics of the study population and costs (hospitalizations, drugs and outpatient examinations/visits) from the National Health Service's perspective. Results: During the observational period 18,344 subjects (5% of the diabetic source population) had at least one hospital admission of interest. Median age (min-max) at the index date was 73(40-102) and 31% of the study population had a Charlson comorbidity index higher than 3. The overall mortality was 11.3 deaths every 100 patient-years (95%C.I., 11.1-11.6). Forty-four percent of the study population had at least one procedure among vascularization, minor and major amputation. Mean cost and corresponding 95% C.I. (€ /patient-year) for PA diabetic patients was 14,085(12,344-16,400) in the index year and around 7,000 in the following periods of observation. Hospitalizations represented the driver of total costs. ConClusions: This study attempted to describe the epidemiologic and economic burden of diabetes patients with PA complications, showing the relevance of related epidemiologic and economic aspects. The following independent variables were determined based on the Eisenberg model: age, gender, race/ethnicity, insurance type, primary care physician, practice region, metropolitan status, practice setting, previous physician office visits, and the type of diabetes medication, and survey year. Multivariate logistic regressions were used for analyses. Results: The estimated population size was 535,158,796 patients with type 2 diabetes, and 3.85% of them were prescribed DPP-4 inhibitors. The most frequently used diabetic medication group was biguanides (metformin) (26.1%), followed by sulfonylurea (17.8%). The use of other diabetes medication was highly associated with the likelihood of the use of DPP-4 inhibitors. Patients who were prescribed sulfonylurea were approximately twice and patients who were prescribed biguanides (metformin) were approximately three times more likely to be prescribed DPP-4 inhibitors (OR = 1.62; p = 0.009 and OR = 2.96; p < 0.001, respectively). The likelihood of the use of DPP-4 inhibitors was also increased with patients receiving insulin (OR = 1.62; p = 0.009). ConClusions: The prescribing of the DPP-4 inhibitors increased with current use of biguanides (metformin), sulfonylureas, and insulin. Decisions were mostly controverse especially in Germany why a comparison with comparable health care systems is required. The international Prismaccess database includes all evaluations and decisions in France and Germany, besides other global authorities. Methods: All decisions for new T2D therapies in 2014 and 2015 which were evaluated by the authorities in France and Germany were systematically searched for. A comparison was executed with a focus on reimbursement decision, basis of decision, acceptance of submitted clinical endpoints, study designs, and comparators. Results: In total there were 9 new therapies evaluated in France by the Transparency Commission. The level of added benefit differed mainly dependent on the combination or monotherapy analyses with other OADs and/or insulin. Five out of 9 drugs had all anti-diabetic drugs as comparators without specific distinction and 8 out of 9 drugs were rated with an ASMR versus the therapeutic strategy. Even though that all therapies received a substantial SMR, most also had some insufficient ratings with respect to monotherapy. All therapies received an ASMR rating of V (no added benefit). In Germany the G-BA evaluated seven drugs. Six therapies received a non-added benefit. Albiglutide was the only therapy receiving an added benefit (non-quantifiable benefit). All comparators were against other active diabetes drugs. One exception was the assessment of canagliflozin in combination with metformin which was not only compared against drugs but against therapeutic strategies. ConClusions: Using the Prismaccess database the analysis shows that there are key differences in the assessment of the same clinical data in T2D. In Germany only one therapy
